Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing

Journal of Applied Genetics

Volumn 56, Issue 2, 2015, Pages 193-198

  Ratajska, Magdalena ^a   Krygier, Magdalena ^a   Stukan, Maciej ^b   Kuźniacka, Alina ^a   Koczkowska, Magdalena ^a   Dudziak, Mirosław ^b   Śniadecki, Marcin ^a   Dębniak, Jarosław ^a   Wydra, Dariusz ^a   Brozek, Izabela ^a   Biernat, Wojciech ^a   Borg, Ake ^c   Limon, Janusz ^a   Wasąg, Bartosz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Gdynia Oncology Centre   (Poland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

BRCA1; BRCA2; Mutations; Next generation sequencing; Ovarian cancer; PARP inhibitors

Indexed keywords

ADULT; AGED; FEMALE; GENETIC SCREENING; GENETICS; GERMLINE MUTATION; HIGH THROUGHPUT SEQUENCING; HUMAN; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OVARY TUMOR; POLAND; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLAND;

EID: 84939969051     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13353-014-0254-5     Document Type: Article

References (31)

1. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251. doi:10.1016/s0140-6736(10)60893-8
2. Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, Deffenbaugh AM, Miron A, Marks JR, Futreal PA, Frank TS (1998) Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4:2433–2437
3. Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, Stukan M, Emerich J, Limon J (2008) High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 108:433–437. doi:10.1016/j.ygyno.2007.09.035
4. Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Pamula-Pilat J, Tecza K, Pekala W, Rembowska J, Nowicka K, Mosor M, Januszkiewicz-Lewandowska D, Rachtan J, Grzybowska E, Nowak J, Steffen J, Limon J (2011) Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 52:325–330. doi:10.1007/s13353-011-0040-6
5. Brozek I, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Rachtan J, Steffen J, Limon J (2012) Limited significance of family history for presence of BRCA1 gene mutation in polish breast and ovarian cancer cases. Fam Cancer 11:351–354. doi:10.1007/s10689-012-9519-5
6. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917. doi:10.1038/nature05789
7. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW (2003) A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31:5526–5533. doi:10.1093/nar/gkg761
8. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. doi:10.1038/nature03445
9. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–134. doi:10.1056/NEJMoa0900212
10. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A’Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512–2519. doi:10.1200/jco.2009.26.9589
11. Gaj P, Kluska A, Nowakowska D, Balabas A, Piatkowska M, Dabrowska M, Niwinska A, Ostrowski J (2012) High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer. Fam Cancer 11:623–628. doi:10.1007/s10689-012-9560-4
12. Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubinski J (2000) Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 66:1963–1968. doi:10.1086/302922
13. Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska L, Haus O, Janiszewska H, Niepsuj S, Gozdz S, Zaremba L, Posmyk M, Pluzanska M, Kilar E, Czudowska D, Wasko B, Miturski R, Kowalczyk JR, Urbanski K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Toloczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojc B, Mierzejewski M, Narod SA, Lubinski J (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686. doi:10.1002/ijc.20162
14. Infante M, Duran M, Acedo A, Sanchez-Tapia EM, Diez-Gomez B, Barroso A, Garcia-Gonzalez M, Feliubadalo L, Lasa A, de la Hoya M, Esteban-Cardenosa E, Diez O, Martinez-Bouzas C, Godino J, Teule A, Osorio A, Lastra E, Gonzalez-Sarmiento R, Miner C, Velasco EA (2013) The highly prevalent BRCA2 mutation c.2808_2811del (3036delACAA) is located in a mutational hotspot and has multiple origins. Carcinogenesis 34:2505–2511. doi:10.1093/carcin/bgt272
15. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–1392. doi:10.1056/NEJMoa1105535
16. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852–861. doi:10.1016/s1470-2045(14)70228-1
17. Lindahl T, Satoh MS, Poirier GG, Klungland A (1995) Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 20:405–411. doi:10.1016/s0968-0004(00)89089-1
18. Lubinski J, Gorski B, Huzarski T, Byrski T, Gronwald J, Serrano-Fernandez P, Domagala W, Chosia M, Ucinski M, Grzybowska E, Lange D, Maka B, Mackiewicz A, Karczewska A, Breborowicz J, Lamperska K, Stawicka M, Gozdecka-Grodecka S, Bebenek M, Sorokin D, Wojnar A, Haus O, Sir J, Mierzwa T, Niepsuj S, Gugala K, Gozdz S, Sygut J, Kozak-Klonowska B, Musiatowicz B, Posmyk M, Kordek R, Morawiec M, Zambrano O, Wasko B, Fudali L, Skret J, Surdyka D, Urbanski K, Mitus J, Rys J, Szwiec M, Rozmiarek A, Dziuba I, Wandzel P, Wisniowski R, Szczylik C, Kozak A, Kozlowski W, Narod SA (2006) BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99:71–76. doi:10.1007/s10549-006-9182-3
19. Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J, Jassem J, De Bock GH (2005) Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104:1004–1012. doi:10.1002/cncr.21276
20. Malander S, Ridderheim M, Masback A, Loman N, Kristoffersson U, Olsson H, Nilbert M, Borg A (2004) One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in southern Sweden. Eur J Cancer 40:422–428. doi:10.1016/j.ejca.2003.09.016
21. Menkiszak J, Gronwald J, Gorski B, Jakubowska A, Huzarski T, Byrski T, Foszczynska-Kloda M, Haus O, Janiszewska H, Perkowska M, Brozek I, Grzybowska E, Zientek H, Gozdz S, Kozak-Klonowska B, Urbanski K, Miturski R, Kowalczyk J, Pluzanska A, Niepsuj S, Koc J, Szwiec M, Drosik K, Mackiewicz A, Lamperska K, Strozyk E, Godlewski D, Stawicka M, Wasko B, Bebenek M, Rozmiarek A, Rzepka-Gorska I, Narod SA, Lubinski J (2003) Hereditary ovarian cancer in Poland. Int J Cancer 106:942–945. doi:10.1002/ijc.11338
22. Miki Y, Swensen J, Shattuckeidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugenstrano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannonalbright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71. doi:10.1126/science.7545954
23. Perkowska M, Brozek I, Wysocka B, Haraldsson K, Sandberg T, Johansson U, Sellberg G, Borg A, Limon J (2003) BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland. Hum Mutat 21:553–554. doi:10.1002/humu.9139
24. Ratajska M, Brozek I, Senkus-Konefka E, Jassem J, Stepnowska M, Palomba G, Pisano M, Casula M, Palmieri G, Borg A, Limon J (2008) BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in northern Poland. Oncol Rep 19:263–268. doi:10.3892/or.19.1.263
25. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710. doi:10.1086/318787
26. Rudnicka H, Debniak T, Cybulski C, Huzarski T, Gronwald J, Lubinski J, Gorski B (2013) Large BRCA1 and BRCA2 genomic rearrangements in polish high-risk breast and ovarian cancer families. Mol Biol Rep 40:6619–6623. doi:10.1007/s11033-013-2775-0
27. Statement of the American Society of Clinical Oncology (1996) Genetic testing for cancer suscepti bility, adopted on February 20, 1996. J Clin Oncol 14(5):1730–1736, discussion 1737–40
28. Szabo C, Masiello A, Ryan JF, Brody LC (2000) The breast cancer information core: database design, structure, and scope. Hum Mutat 16:123–131. doi:10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y
29. Szwiec M, Jakubowska A, Gorski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, Debniak T, Byrski T, Kluzniak W, Wokolorczyk D, Birkenfeld B, Akbari MR, Narod SA, Lubiński J, Cybulski C (2014) Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. Clin Genet. doi:10.1111/cge.12360
30. van Der Looij M, Wysocka B, Brozek I, Jassem J, Limon J, Olah E (2000) Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from north-eastern Poland. Hum Mutat 15:480–481. doi:10.1002/(SICI)1098-1004(200005)15:5<480::AID-HUMU13>3.0.CO;2-G
31. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rices C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792. doi:10.1038/378789a0